PMC10235594_01
(A) Before treatment, an erythematous, poorly demarcated lesion (6 cm x 5 cm) on the back. (B) After two years of sirolimus treatment, the lesion regressed completely.
fonc-13-1132702-g001.jpg
PMC10235594_01_fonc-13-1132702-g001.jpg
f1
Physical examination revealed an erythematous, poorly demarcated lesion (6 cm x 5 cm) on the patient's back with no signs of inflammation or pain ( Figure 1A ). The patient achieved complete response after two years of sirolimus treatment (Figures 1B, 2E, F).
(A, B) Magnetic resonance imaging showed ill-defined margins, diffusive hyperintense signals on fat-suppressed T2 weighted images (black arrow designates the lesion). (C, D) After one year of sirolimus treatment, the lesion shrank dramatically (black arrow designates the lesion). (E, F) After two years of sirolimus treatment, the lesion regressed completely.
fonc-13-1132702-g002.jpg
PMC10235594_01_fonc-13-1132702-g002.jpg
f2
The lesion shrank dramatically after one year of sirolimus therapy (Figures 2C, D). The patient achieved complete response after two years of sirolimus treatment (Figures 1B, 2E, F).
(A) Typical glomeruloid areas with spindle shaped cells following hematoxylin and eosin staining. (B-F) Immunohistochemical staining was positive for D2-40, PROX-1, LYVE-1, CD31 and CD34, respectively.
fonc-13-1132702-g003.jpg
PMC10235594_01_fonc-13-1132702-g003.jpg
f3
Immunohistochemical staining was positive for D2-40, PROX-1, LYVE-1, CD31 and CD34 ( Figure 3 ).